▲ +637.13% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Liquidia Technologies in the last 3 months. The average price target is $22.67, with a high forecast of $40.00 and a low forecast of $4.00. The average price target represents a 637.13% upside from the last price of $3.08.
The current consensus among 3 contributing investment analysts is to buy stock in Liquidia Technologies. This rating has held steady since February 2020, when it changed from a Hold consensus rating.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.